Huma.

Huma is a London-based digital health technology company. Its product is not a single app but a regulated, modular platform that partners use to run remote patient monitoring, "hospital at home" programs, disease-specific companion apps and decentralized clinical trials. The company combines predictive algorithms, digital biomarkers and real-world data so care teams can see how a patient is doing between visits, not just during them.

The idea traces back to a Johns Hopkins laboratory. Founder and chief executive Dan Vahdat, then a bioengineering PhD student who grew up in a family of doctors, noticed that hospitals know an enormous amount about a patient inside their walls and almost nothing once that patient leaves. He left the degree unfinished to build a company aimed at bringing that visibility back to the care team - making medicine, in his words, more proactive and predictive rather than reactive.

Founded in 2011 as Medopad, the company spent years doing the slow, difficult work that consumer health apps tend to skip: medical-device regulation, hospital integration and clinical evidence. In April 2020, as the COVID-19 pandemic sent demand for remote care soaring, Medopad rebranded to Huma, acquired two British health-tech firms - BioBeats and Tarilian Laser Technologies - and appointed former UK Health Secretary Alan Milburn as its first chairperson.

The name itself carries a story. The rebrand, designed by studio Koto, drew on Leonardo da Vinci's Vitruvian Man to signal whole-person health, and on the Huma bird of Persian mythology, a creature associated with good fortune and wellbeing. It marked a shift in ambition: from monitoring one disease at a time to a broader mission around physical and mental health.

Huma's Software as a Medical Device is described as the only disease- and device-agnostic platform to simultaneously hold EU MDR Class IIb, US FDA (510(k)) Class II clearance and UK MHRA Class IIb registration. Crucially, the platform is regulated to accept artificial-intelligence algorithms and to monitor patients of any age. For a hospital or drugmaker, that means a new tool can be configured on an already-cleared foundation instead of starting a multi-year approval process from zero.

That is the difference between selling a product and selling rails. Competitors in remote monitoring and decentralized trials - names such as Biofourmis, Current Health, Medable and BioIntelliSense - tend to lead with specific applications or hardware. Huma leads with the platform, then lets partners such as AstraZeneca and Bayer build the applications. Its AI work, developed in part with Google, layers predictive algorithms and digital biomarkers on top so that a decline can be flagged earlier.

The expertise behind it is deliberately cross-disciplinary: clinicians, engineers, data scientists and regulatory specialists working in the same building. That mix is what lets Huma make medical-grade claims rather than wellness-grade ones - the distinction between a dashboard that suggests you might be unwell and software that a clinician can act on.

It has not been a straight line. Alongside its 2024 Series D, Huma cut staff as it refocused on the platform strategy and the digital-health sector went through a broader correction. The reset is part of the story: a company narrowing to the thing it does best after a decade of expansion.